Mario Campone
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3.
Goetz M, Toi M, Huober J, Sohn J, Trédan O, Park I, Campone M, Chen S, Manso L, Paluch-Shimon S, Freedman O, O'Shaughnessy J, Pivot X, Tolaney S, Hurvitz S, Llombart-Cussac A, Andre V, Saha A, van Hal G, Shahir A, Iwata H, Johnston S. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3. Ann Oncol 2024
08.05.2024Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3.
08.05.2024Ann Oncol 2024
Goetz Matthew P, Toi Masakazu, Huober Jens, Sohn Joo Hyuk, Trédan Olivier, Park In Hae, Campone Mario, Chen S-C, Manso L M, Paluch-Shimon Shani, Freedman Orit C, O'Shaughnessy Joyce, Pivot X, Tolaney Sara M, Hurvitz Sara A, Llombart-Cussac Antonio, Andre Valerie A M, Saha A, van Hal G, Shahir Ashwin, Iwata H, Johnston Stephen R D
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.
Johnston S, Toi M, O'Shaughnessy J, Rastogi P, Campone M, Neven P, Huang C, Huober J, Jaliffe G, Cicin I, Tolaney S, Goetz M, Rugo H, Senkus E, Testa L, Del Mastro L, Shimizu C, Wei R, Shahir A, Munoz M, San Antonio B, Andre V, Harbeck N, Martín M. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol 2022
05.12.2022Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.
05.12.2022Lancet Oncol 2022
Johnston Stephen R D, Toi Masakazu, O'Shaughnessy Joyce, Rastogi Priya, Campone Mario, Neven Patrick, Huang Chiun-Sheng, Huober Jens, Jaliffe Georgina Garnica, Cicin Irfan, Tolaney Sara M, Goetz Matthew P, Rugo Hope S, Senkus Elzbieta, Testa Laura, Del Mastro Lucia, Shimizu Chikako, Wei Ran, Shahir Ashwin, Munoz Maria, San Antonio Belen, Andre Valerie, Harbeck Nadia, Martín Miguel
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
Johnston S, Huober J, Wardley A, Tolaney S, Cicin I, Smith I, Frenzel M, Headley D, Wei R, San Antonio B, Hulstijn M, Cox J, O'Shaughnessy J, Rastogi P, Cortes J, Neven P, Harbeck N, Hegg R, Toi M, Martín M, Shao Z, Zhang Q, Martinez Rodriguez J, Campone M, Hamilton E, Sohn J, Guarneri V, Okada M, Boyle F, monarchE Committee Members and Investigators. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol 2020; 38:3987-3998.
20.09.2020Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
20.09.2020J Clin Oncol 2020; 38:3987-3998
Johnston Stephen R D, Huober Jens, Wardley Andrew, Tolaney Sara M, Cicin Irfan, Smith Ian C, Frenzel Martin, Headley Desirée, Wei Ran, San Antonio Belen, Hulstijn Maarten, Cox Joanne, O'Shaughnessy Joyce, Rastogi Priya, Cortes Javier, Neven Patrick, Harbeck Nadia, Hegg Roberto, Toi Masakazu, Martín Miguel, Shao Zhi Min, Zhang Qing Yuan, Martinez Rodriguez Jorge Luis, Campone Mario, Hamilton Erika, Sohn Joohyuk, Guarneri Valentina, Okada Morihito, Boyle Frances, monarchE Committee Members and Investigators
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Goetz M, Bourayou N, Smith I, Barriga S, Frenzel M, Forrester T, Garnica Jaliffe G, Freedman O, Manso L, Chen S, Trédan O, Park I, Huober J, Paluch-Shimon S, Sohn J, Campone M, Toi M, Di Leo A. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol 2017; 35:3638-3646.
02.10.2017MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
02.10.2017J Clin Oncol 2017; 35:3638-3646
Goetz Matthew P, Bourayou Nawel, Smith Ian C, Barriga Susana, Frenzel Martin, Forrester Tammy, Garnica Jaliffe Georgina, Freedman Orit C, Manso Luis, Chen Shin-Cheh, Trédan Olivier, Park In Hae, Huober Jens, Paluch-Shimon Shani, Sohn Joohyuk, Campone Mario, Toi Masakazu, Di Leo Angelo
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)
Wick W, Golfinopoulos V, Frenel J, Campone M, Ricard D, Marosi C, Villa S, Weyerbrock A, Hopkins K, Homicsko K, Lhermitte B, Pesce G, Roth P, Stupp R, Gorlia T, Bady P, Platten M, van den Bent M, Taphoorn M, Steuve J, Brandes A, Hamou M, Wick A, Kosch M, Weller M, Hegi M. Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082). Clin Cancer Res 2016; 22:4797-4806.
03.05.2016Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)
03.05.2016Clin Cancer Res 2016; 22:4797-4806
Wick Wolfgang, Golfinopoulos Vassilis, Frenel Jean-Sebastien, Campone Mario, Ricard Damien, Marosi Christine, Villa Salvador, Weyerbrock Astrid, Hopkins Kirsten, Homicsko Krisztian, Lhermitte Benoit, Pesce Gianfranco, Roth Patrick, Stupp Roger, Gorlia Thierry, Bady Pierre, Platten Michael, van den Bent Martin J, Taphoorn Martin J B, Steuve Jonathan, Brandes Alba A, Hamou Marie-France, Wick Antje, Kosch Markus, Weller Michael, Hegi Monika E
Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences
Decensi A, Coates A, Goldhirsch A, Gelber R, Price K, Johansson H, Zaman K, Schönenberger A, Debled M, Campone M, Monnier A, Tondini C, McIntosh C, Thürlimann B, Guerrieri-Gonzaga A, Sun Z, Aebi S. Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences. Breast Cancer Res Treat 2014; 144:321-9.
01.02.2014Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences
01.02.2014Breast Cancer Res Treat 2014; 144:321-9
Decensi Andrea, Coates Alan S, Goldhirsch Aron, Gelber Richard D, Price Karen N, Johansson Harriet, Zaman Khalil, Schönenberger Astrid, Debled Marc, Campone Mario, Monnier Alain, Tondini Carlo, McIntosh Christina, Thürlimann Beat, Guerrieri-Gonzaga Aliana, Sun Zhuoxin, Aebi Stefan